Home
Storia in 2 fonti
Novo's next-gen obesity drug shows positive results, heads to late-stage testing
Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
- ·
cnbc.com
Novo's next-gen obesity drug shows positive results, heads to late-stage testing
Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
- ·
ft.com
New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline